# Phase I/II Study of SyB L-0501RI in Combination With Rituximab to Treat Lymphoma

> **NCT03900377** · PHASE1,PHASE2 · COMPLETED · sponsor: **SymBio Pharmaceuticals** · enrollment: 37 (actual)

## Conditions studied

- Lymphoma, B-cell, Diffuse

## Interventions

- **DRUG:** SyB L-0501RI

## Key facts

- **NCT ID:** NCT03900377
- **Lead sponsor:** SymBio Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-01
- **Primary completion:** 2020-09-09
- **Final completion:** 2021-02-26
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2023-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03900377

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03900377, "Phase I/II Study of SyB L-0501RI in Combination With Rituximab to Treat Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03900377. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*